Search Prime Grants

HT94252310376

Project Grant

Overview

Grant Description
Late-stage preclinical development of teixobactin to treat drug-resistant infections.
Awardee
Novobiotic Pharmaceuticals
Grant Program (CFDA)
12.420 - Military Medical Research and Development
Awarding / Funding Agency
Defense Health Agency (DHA) [DoD]
Place of Performance
Cambridge, Massachusetts 021381044 United States
Geographic Scope
Single Zip Code
Related Opportunity
W81XWH22JWMRPMMRDA
Novobiotic Pharmaceuticals was awarded Late-stage Development of Teixobactin for Drug-Resistant Infections Project Grant HT94252310376 worth $4,499,475 from Defense Health Agency in May 2023 with work to be completed primarily in Cambridge Massachusetts United States. The grant has a duration of 3 years and was awarded through assistance program 12.420 Military Medical Research and Development.

Status
(Ongoing)

Last Modified 4/27/23

Period of Performance
5/1/23
Start Date
4/30/26
End Date
78.0% Complete

Funding Split
$4.5M
Federal Obligation
$0.0
Non-Federal Obligation
$4.5M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to HT94252310376

Additional Detail

Award ID FAIN
HT94252310376
SAI Number
None
Award ID URI
None
Awardee Classifications
For-Profit Organization (Other Than Small Business)
Other
Awarding Office
HT9425 ARMY MED RES ACQ ACTIVITY
Funding Office
HT0989 CONG DIR MED RES PRGM / CDMRP - MM
Awardee UEI
GUV4CZLZE5Z2
Awardee CAGE
48R19
Performance District
05
Senators
Edward Markey
Elizabeth Warren
Representative
Katherine Clark

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
Defense Health Program, Defense (097-0130) Department of Defense-Military Grants, subsidies, and contributions (41.0) $4,499,475 100%
Modified: 4/27/23